Arvinas Inc ARVN:NASDAQ

Last Price$51.61NASDAQ Closing Price as of 4:00PM ET 1/28/20

Today's Change+0.78(1.53%)
Bid (Size)$51.61 (1)
Ask (Size)$51.63 (6)
Day Low / High$50.45 - 52.17
Volume221.6 K
 

View Biotechnology IndustryPeer Comparison as of 01/28/2020

 

Arvinas Inc ( NASDAQ )

Price: $51.61
Change: +0.78 (1.53%)
Volume: 221.6 K
4:00PM ET 1/28/2020
 
 

Epizyme Inc ( NASDAQ )

Price: $21.81
Change: +0.45 (2.11%)
Volume: 1.1 M
4:00PM ET 1/28/2020
 
 

Xencor Inc ( NASDAQ )

Price: $33.78
Change: +0.77 (2.35%)
Volume: 211.6 K
3:59PM ET 1/28/2020
 
 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $32.82
Change: +0.76 (2.37%)
Volume: 945.9 K
4:00PM ET 1/28/2020
 
 

Eidos Therapeutics Inc ( NASDAQ )

Price: $53.18
Change: -1.06 (1.95%)
Volume: 120.8 K
4:00PM ET 1/28/2020
 

Read more news Recent News

--Analyst Actions: Wedbush Boosts Price Target on Arvinas to $60 From $39 on 'Catalyst-Filled' 2020, Keeps Outperform Rating
6:44AM ET 1/24/2020 MT Newswires

Price: 50.86, Change: +0.12, Percent Change: +0.24 ...

Analyst Actions: Piper Sandler Raises Arvinas' Price Target to $58 From $35, Reiterates Overweight Rating
12:28PM ET 1/06/2020 MT Newswires

Arvinas (ARVN) has an average analyst rating of buy, with an average price target of $44. Price: 43.19, Change: +1.57, Percent Change: +3.77 ...

Analyst Actions: Cantor Fitzgerald Lifts Arvinas' Price Target to $75 From $42, Reiterates Overweight Rating
10:36AM ET 12/20/2019 MT Newswires

Arvinas (ARVN) has an average analyst rating of buy, with an average price target of $42. Price: 40.18, Change: +0.48, Percent Change: +1.21 ...

Analyst Actions: HC Wainwright Starts Arvinas at Buy With $50 Price Target
11:05AM ET 12/19/2019 MT Newswires

Arvinas (ARVN) has an average analyst rating of buy, with an average price target of $38. Price: 40.80, Change: -0.04, Percent Change: -0.10 ...

View all Commentary and Analysis

The Cutting Edge Of Systematic Investing
12:48PM ET 1/21/2020 Seeking Alpha

Biotech Bonanza: 2020 Outlook In An Election Year
4:15PM ET 1/08/2020 Seeking Alpha

Week 2 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
7:19AM ET 1/05/2020 Seeking Alpha

Week 51 Breakout Forecast: Short-Term Picks To Give You An Edge
8:35AM ET 12/15/2019 Seeking Alpha

Company Profile

Business DescriptionArvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT. View company web site for more details
Address5 Science Park
New Haven, Connecticut 06511
Phone+1.203.535.1456
Number of Employees83
Recent SEC Filing12/19/20194
Chief Executive Officer, President & DirectorJohn G. Houston
Chief Financial OfficerSean A. Cassidy
Chief Technology OfficerAndy Crew
Chief Scientific OfficerIan Taylor

Company Highlights

Price Open$51.19
Previous Close$50.83
52 Week Range$14.07 - 52.93
Market Capitalization$1.7 B
Shares Outstanding33.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/24/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.23
Beta vs. S&P 500N/A
Revenue$14.3 M
Net Profit Margin-157.34%
Return on Equity-50.74%

Analyst Ratings as of 12/18/2019

Buy
9
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset